Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Thoracic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm

Cancer Family

Thoracic Neoplasm

CI-CAN-00000054Explore in graph →

Non-malignant2,891 active trials51 approved drugs626 evidence items

NCIt: C3406
MeSH: D013899

Overview
Statistics
Survival
Genomics51
Variants & evidence626
Drugs128
Trials12160
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (479)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 426–450 of 479 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.
· Clin Cancer Res · 2018 · PMID 29127119 · validated civic_curation pubmed
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
· Nat Commun · 2019 · PMID 31399568 · validated civic_curation pubmed
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
· EBioMedicine · 2016 · PMID 26870817 · validated civic_curation pubmed
High-throughput Phenotyping of Lung Cancer Somatic Mutations.
· Cancer Cell · 2016 · PMID 27478040 · validated civic_curation pubmed
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
· PLoS One · 2007 · PMID 17726540 · validated civic_curation pubmed
Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
· Anticancer Res · 2015 · PMID 25862853 · validated civic_curation pubmed
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
· Cell Oncol (Dordr) · 2013 · PMID 23619944 · validated

Showing 426–450 of 479 publications

← Previous
1
…
17
18
19
20
Next →

civic_curation

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.

· J Thorac Oncol · 2011 · PMID 21964527 · validated civic_curation pubmed

ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.

· Respirology · 2011 · PMID 21883677 · validated civic_curation pubmed

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

· Oncotarget · 2015 · PMID 26515464 · validated civic_curation pubmed

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

· J Clin Invest · 2006 · PMID 16906227 · validated civic_curation pubmed

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

· Cancer Res · 2008 · PMID 18451166 · validated civic_curation pubmed

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

· Clin Cancer Res · 2008 · PMID 18594010 · validated civic_curation pubmed

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

· Clin Cancer Res · 2012 · PMID 22912387 · validated civic_curation pubmed

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

· Oncotarget · 2017 · PMID 28947956 · validated civic_curation pubmed

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.

· Oncotarget · 2016 · PMID 26689995 · validated civic_curation pubmed

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

· Int J Mol Med · 2009 · PMID 19513541 · validated civic_curation pubmed

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.

· Int J Cancer · 2012 · PMID 21732342 · validated civic_curation pubmed

Characteristics of lung cancers harboring NRAS mutations.

· Clin Cancer Res · 2013 · PMID 23515407 · validated civic_curation pubmed

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

· Cancer Res · 2008 · PMID 18632602 · validated civic_curation pubmed

Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.

· Cell Death Dis · 2021 · PMID 34247201 · validated civic_curation pubmed

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

· Cancer Cell · 2010 · PMID 20609353 · validated civic_curation pubmed

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.

· Oncotarget · 2016 · PMID 27612423 · validated civic_curation pubmed

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

· Clin Cancer Res · 2008 · PMID 18927303 · validated civic_curation pubmed

Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.

· Mol Carcinog · 2017 · PMID 26894620 · validated civic_curation pubmed